Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Work In Process (2023 - 2025)

Maxcyte (MXCT) has disclosed Work In Process for 3 consecutive years, with $501000.0 as the latest value for Q4 2025.

  • Quarterly Work In Process rose 85.56% to $501000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $501000.0 through Dec 2025, up 85.56% year-over-year, with the annual reading at $501000.0 for FY2025, 85.56% up from the prior year.
  • Work In Process for Q4 2025 was $501000.0 at Maxcyte, up from $400000.0 in the prior quarter.
  • The five-year high for Work In Process was $1.0 million in Q2 2023, with the low at $101000.0 in Q2 2024.
  • Average Work In Process over 3 years is $445016.7, with a median of $368500.0 recorded in 2025.
  • The sharpest move saw Work In Process tumbled 89.93% in 2024, then soared 233.66% in 2025.
  • Over 3 years, Work In Process stood at $558000.0 in 2023, then crashed by 51.61% to $270000.0 in 2024, then soared by 85.56% to $501000.0 in 2025.
  • According to Business Quant data, Work In Process over the past three periods came in at $501000.0, $400000.0, and $337000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.